drugset

drugset / Trial / NCT00517920

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

NCT00517920 ↗

Phase 2 Completed 44 enrolled AbbVie Genentech, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Timeline

Start: 2007-09
Primary completion: 2011-06
Completion: 2012-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ABT-869	Unknown	0.25 mg/kg	—

Indications